# Catalio Capital Management, LP 13F Q2 2026: $532 million

Catalio Capital Management, LP reported $532 million in 13F securities across 39 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Avalyn Pharmaceuticals Inc at $55.2 million, 10.4% of the reported value. Since Q1 2026 it opened 11 new positions and exited 13.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $532,102,416
- Positions: 39
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1958125
- Form 13F file number: 028-25237
- CRD number: 310374
- Business address: 512 W. 22nd Street 5th Floor, New York, NY 10011
- SEC filing: [0001958125-26-000005](https://www.sec.gov/Archives/edgar/data/1958125/000195812526000005/0001958125-26-000005-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/catalio-capital-management-lp-310374)

## Top 25 holdings by value

The largest of 39 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Avalyn Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/avalyn-pharmaceuticals-inc-05348y105) | COM SHS | 1,675,830 | $55.2 million | New |
| [Johnson & Johnson](https://specstream.ai/data/institutional-holders/johnson-johnson-478160104) | COM | 138,946 | $35.3 million | New |
| [Gilead Sciences Inc](https://specstream.ai/data/institutional-holders/gilead-sciences-inc-375558103) | COM | 269,309 | $34 million | +105,404 |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806x102) | COM | 455,041 | $33.9 million | +23,027 |
| [Syndax Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/syndax-pharmaceuticals-inc-87164f105) | COM | 1,215,698 | $26.6 million | +172,028 |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 562,672 | $26.5 million | -475,312 |
| [Bristol-Myers Squibb Co](https://specstream.ai/data/institutional-holders/bristol-myers-squibb-co-110122108) | COM | 412,961 | $23.8 million | -7,766 |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 824,043 | $22.6 million | New |
| [Natera Inc](https://specstream.ai/data/institutional-holders/natera-inc-632307104) | COM | 82,181 | $22.3 million | +11,274 |
| [Incyte Corp](https://specstream.ai/data/institutional-holders/incyte-corp-45337c102) | COM | 191,627 | $21.7 million | +9,526 |
| [Septerna Inc](https://specstream.ai/data/institutional-holders/septerna-inc-81734d104) | COM | 536,152 | $18 million | +241,792 |
| [Mineralys Therapeutics Inc](https://specstream.ai/data/institutional-holders/mineralys-therapeutics-inc-603170101) | COM | 648,722 | $17.5 million | +209,681 |
| [Heartflow Inc](https://specstream.ai/data/institutional-holders/heartflow-inc-42238d107) | COM | 583,055 | $17.1 million | +179,467 |
| [Corvus Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/corvus-pharmaceuticals-inc-221015100) | COM | 1,080,888 | $16.1 million | +188,955 |
| [Structure Therapeutics Inc](https://specstream.ai/data/institutional-holders/structure-therapeutics-inc-86366e106) | SPONSORED ADS | 276,550 | $14.8 million | +21,171 |
| [Protagonist Therapeutics Inc](https://specstream.ai/data/institutional-holders/protagonist-therapeutics-inc-74366e102) | COM | 106,799 | $13.1 million | New |
| [Disc Medicine Inc](https://specstream.ai/data/institutional-holders/disc-medicine-inc-254604101) | COM | 159,384 | $11.7 million | +36,406 |
| [Edwards Lifesciences Corp](https://specstream.ai/data/institutional-holders/edwards-lifesciences-corp-28176e108) | COM | 124,778 | $11.3 million | -19,829 |
| [Axsome Therapeutics Inc.](https://specstream.ai/data/institutional-holders/axsome-therapeutics-inc-05464t104) | COM | 43,182 | $10.6 million | New |
| [Ultragenyx Pharmaceutical in](https://specstream.ai/data/institutional-holders/ultragenyx-pharmaceutical-in-90400d108) | COM | 316,252 | $10.6 million | -534,545 |
| [Kailera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kailera-therapeutics-inc-482931102) | COMMON STOCK | 468,750 | $10.3 million | New |
| [Karyopharm Therapeutics Inc](https://specstream.ai/data/institutional-holders/karyopharm-therapeutics-inc-48576u205) | COM NEW | 940,855 | $9.2 million | +43,146 |
| [Odyssey Therapeutics Inc](https://specstream.ai/data/institutional-holders/odyssey-therapeutics-inc-67613t104) | COMMON STOCK | 457,839 | $8.6 million | New |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 31,759 | $8.5 million | New |
| [Kardigan Inc](https://specstream.ai/data/institutional-holders/kardigan-inc-485925101) | COM | 312,500 | $7.5 million | New |

## New positions in Q2 2026

11 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Avalyn Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/avalyn-pharmaceuticals-inc-05348y105) | COM SHS | 1,675,830 | $55.2 million |
| [Johnson & Johnson](https://specstream.ai/data/institutional-holders/johnson-johnson-478160104) | COM | 138,946 | $35.3 million |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 824,043 | $22.6 million |
| [Protagonist Therapeutics Inc](https://specstream.ai/data/institutional-holders/protagonist-therapeutics-inc-74366e102) | COM | 106,799 | $13.1 million |
| [Axsome Therapeutics Inc.](https://specstream.ai/data/institutional-holders/axsome-therapeutics-inc-05464t104) | COM | 43,182 | $10.6 million |
| [Kailera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kailera-therapeutics-inc-482931102) | COMMON STOCK | 468,750 | $10.3 million |
| [Odyssey Therapeutics Inc](https://specstream.ai/data/institutional-holders/odyssey-therapeutics-inc-67613t104) | COMMON STOCK | 457,839 | $8.6 million |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 31,759 | $8.5 million |
| [Kardigan Inc](https://specstream.ai/data/institutional-holders/kardigan-inc-485925101) | COM | 312,500 | $7.5 million |
| [4d Molecular Therapeutics in](https://specstream.ai/data/institutional-holders/4d-molecular-therapeutics-in-35104e100) | COM | 471,254 | $6.3 million |
| [Bridgebio Oncology Therapeut](https://specstream.ai/data/institutional-holders/bridgebio-oncology-therapeut-107924102) | COM NEW | 318,407 | $2.4 million |

## Positions exited in Q2 2026

13 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Ascendis Pharma A/S | SPONSORED ADR | 129,111 | $29.5 million |
| Terns Pharmaceuticals Inc | COM | 409,031 | $21.6 million |
| Soleno Therapeutics Inc | COM | 577,808 | $19.3 million |
| [Boston Scientific Corp](https://specstream.ai/data/institutional-holders/boston-scientific-corp-101137107) | COM | 299,318 | $18.8 million |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 215,501 | $14.2 million |
| [Adaptive Biotechnologies Cor](https://specstream.ai/data/institutional-holders/adaptive-biotechnologies-cor-00650f109) | COM | 722,784 | $10 million |
| Kalvista Pharmaceuticals Inc | COM | 426,551 | $8.6 million |
| [Uniqure NV](https://specstream.ai/data/institutional-holders/uniqure-nv-n90064101) | SHS | 491,116 | $8 million |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 47,193 | $5.3 million |
| [Supernus Pharmaceuticals](https://specstream.ai/data/institutional-holders/supernus-pharmaceuticals-868459108) | COM | 62,019 | $3.2 million |
| [Phathom Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/phathom-pharmaceuticals-inc-71722w107) | COM | 247,767 | $2.8 million |
| [Newamsterdam Pharma Company](https://specstream.ai/data/institutional-holders/newamsterdam-pharma-company-n62509109) | ORDINARY SHARES | 83,554 | $2.7 million |
| [Tyra Biosciences Inc](https://specstream.ai/data/institutional-holders/tyra-biosciences-inc-90240b106) | COM | 67,285 | $2.6 million |

## Also on SpecStream

- [Catalio Capital Management, LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1958125/000195812526000005/0001958125-26-000005-index.htm)
- [Catalio Capital Management, LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/catalio-capital-management-lp-310374)
- [Largest 13F filers in New York](https://specstream.ai/data/institutional-holdings/state/new-york)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New York, New York

- [Urology practices in New York, New York](https://specstream.ai/data/businesses/urology-practices/new-york-new-york-united-states)
- [Medical schools in New York, New York](https://specstream.ai/data/businesses/medical-schools/new-york-new-york-united-states)
- [Cosmetic surgery practices in New York, New York](https://specstream.ai/data/businesses/cosmetic-surgery-practices/new-york-new-york-united-states)
- [Steakhouses in New York, New York](https://specstream.ai/data/businesses/steakhouses/new-york-new-york-united-states)
- [IT companies in New York, New York](https://specstream.ai/data/businesses/it-companies/new-york-new-york-united-states)
- [Cafes in New York, New York](https://specstream.ai/data/businesses/cafes/new-york-new-york-united-states)
